Short title: Risk estimation of placental abruption 2 CONDENSATION Prior second trimester, third trimester, and repeated fetal loss may be used to predict increased risk of placental abruption.
INTRODUCTION
Placentae abruption is a major cause of both fetal and maternal morbidity and mortality. It occurs in 0.4% to 1.3% of all pregnancies. Placenta abruption usually presents as a 1 combination of vaginal bleeding, uterine contractions, and pain. The perinatal mortality rate varies between 2% and 67%, depending on gestational age, fetal weight, and the degree of abruption. About half of perinatal deaths due to placental abruption occur in utero, which 12 also makes this disorder a major contributor to stillbirth. The etiology of placental 2, 3 abruption is unknown, but it occurs more frequently among smokers, in hypertensive pregnancies, in pregnancies with intrauterine growth restriction (IUGR), in instances of trauma, with advancing maternal age, in male fetuses, and in women with a previous placental abruption. 4 Recently, placental abruption has been reported to be more prevalent in thrombophilic pregnancies and in women with a familial history of venous thromboembolism. 56 Most risk factors for placental abruption are also related to increased risk of venous thromboembolism. It is currently not known whether prior second trimester-, third trimester-, or repeated fetal loss also are related to increased risk of placental abruption
The aim of this study was to determine if the above mentioned variables are related to placental abruption and to construct risk score in the prediction of placental abruption.
MATERIALS AND METHODS
The Ethics Committee of Lund University approved the study design. All medical records with a diagnosis of placental abruption at the Department of Obstetrics and Gynecology, University Hospital Malmö, for an eight-year period (January 1992 to December 1999) were scrutinized. Out of the 24,207 pregnancies, we identified 175 (0.7%) cases of placental abruption in 161 women, and 112 accepted to participate in the study. All medical records were scrutinized and a majority of the women underwent a detailed in-person interview regarding their medical history. The cases were compared with a prospectively-collected, unselected population of 2,371 gravidae without placental abruption. 7 We defined placental abruption in terms of a clinical diagnosis, usually based on profuse vaginal bleeding appearing during the third trimester, painful contractions, and clinical examination of the placentae. In women with more than one episode of placental abruption only the last one was included.
First trimester fetal loss was defined as fetal loss before 13 weeks of gestation; second trimester fetal loss as between 13 and 26 weeks of gestation; and stillbirth as intrauterine death > 26 weeks of gestation. Repeated fetal loss was defined as at least three first trimester fetal losses or two second trimester fetal losses.
Smoking habits were recorded at the first visit to the antenatal clinic, which occurred at a mean of 12 weeks of gestation (standard deviation [SD] 3.3 weeks), whereby smokers were defined as those who smoked every day. High maternal age was defined as maternal age abowe 35.
Preeclampsia was defined as pregnancy-induced hypertension and proteinuria > 0.3 g/1 (Albustix Boehringer Mannheim > 1+). Pregnancy-induced hypertension was defined as a resting diastolic blood pressure > 90 mm Hg, measured on two occasions at an interval of at least five hours, and developing after 20 weeks of gestation in a previously normotensive pregnancy.
Gestational age was estimated by ultrasonographic measurement of biparietal diameter and femur length in 96% of the cases, and from the date of the last menstrual period in the remaining 4%.
Small-for-gestational age (SGA) was used as an approximation of IUGR. SGA was defined as a newborn with a birth weight 2 SD units or more below the mean for a Swedish reference population. This corresponds to a birth weight deviation < -22%, with birth weight 
R E S U L T S
The characteristics of both placental abruption cases and the control population are shown in Table 1 . We might note that as expected, the outcome measures such as gestational age, birth weight, umbilical pH, and stillbirth, differ between abruptio cases and controls. Placental abruption group was also characterised by a significantly higher prevalence of smokers, IUGR, preeclampsia, low APGAR scores, and Cesarean delivery. The placental abruption In Table 2 we present the bivariate OR of selected pregnancy variables regarding the risk of developing placental abruption. Previous second trimester and repeated fetal loss were significantly associated with increased risk of placental abruption (p < 0.01, and p = 0.02, respectively). Women with prior stillbirths or prior placental abruption were related to highly significantly increased risk for placental abruption (p < 0.001, and p < 0.001, respectively).
Women with preeclampsia was associated with a three-fold increased risk of placental Based on these data a risk score was constructed with the assumption of a multiplicatory relationship between risk factors. Most risk factors were at roughly 3-fold increased risk and were assigned 1 point for each of the following risk factors; smoking, second trimester fetal loss, third trimester fetal loss, repeated fetal loss, multiple pregnancy, preeclampsia, IUGR, family history of thromboembolism, or high maternal age. Prior stillbirth was assigned 2 points and prior placental abruption 3 points. The risk points were added, forming a risk score and the distribution of risk is presented in Table 3 . Using the group with risk score 0 as reference, OR for risk of placental abruption were calculated for each risk score. The risk increased from OR 2.7 for risk score 1, to OR 94.5 for risk score > 4. The design of the study does not permit calculation of positive and negative predictive values.
DISCUSSION
In this study we have tried to estimate the risk of developing placental abruption based on known variables available before delivery. Placenta abruptio has been identified as a major cause of stillbirth. However, that a history of third trimester fetal loss poses a large risk factor for placental abruption has, to the best of our knowledge, previously not been reported. We found that women with a history of a second trimester fetal loss, and those who suffered repeated fetal loss were associated with a 3.2-fold and 3.4-fold increased risk of placental abruption.
Of interest for this study is that most variables, which were significantly associated with an increased risk of placental abruption are also related to an increased risk of venous thromboembolism. Although not assessed in this study women with thrombophilias have been reported to be at increased risk of pregnancy complications, including preeclampsia, placental abruption and IUGR. In a prior report on almost the same material, carriers of the 5 factor V Leiden mutation were at a non-significant 50% increased risk of placental abruption (odds ratio [OR] = 1.5, 95% confidence interval [CI] 0.9-1.6). Thus, we do not consider 6 carriership of FV Leiden as a significant risk factor for placental abruption. In addition, women with family history of venous thromboembolism were at a 3-fold increased risk of placental abruption. Women with a history of third trimester fetal loss have also been smokers (> 10 cigarettes per day, OR = 1.4, 95% CI 1.1-1.9). Second trimester fetal loss 11 has been associated with maternal thrombohilia. 9 Regarding factors previously known to be related to placental abruption, our findings of a 3-fold increased risk of placental abruption in pregnancies with IUGR fetuses is in a similar range as Kramer and co-workers. However, they subdivided their results into women with 4 fetuses between mild IUGR < -15% and > -25% (OR = 1.3) and severe IUGR < -25% (OR = 4.0).
Our estimates regarding risk of placental abruption in preeclamptic women differ somewhat from that of Kramer and co-workers. They reported a doubled risk of developing placental We believe that these results might be of clinical value in assessment of women with third trimester hemorrhage or premature contractions. The usual risk assessment for include clinical status, anamnesis of previous placental abruption and the presence of IUGR, preeclampsia, high maternal age, duplex pregnancy, family history of venous thromboembolism, and maternal smoking. However, a history of second, third trimester fetal loss, repeated fetal loss, or the knowledge of thrombophilia, might improve the risk assessment and help to identify a high risk group for developing placental abruption and might benefit from more intense surveillance. Our findings need to be reproduced by other groups in order to be generalized. If validated, this approach will also give us the opportunity to identify a subgroup at increased risk and would also enable early pathophysiological research.
Although the average Hb values did not differ between placental abruption cases and controls, we found low final Hb values in 22% of the placental abruption group, as compared to 11% in the control group (OR = 2.2, 95% CI 1.3-3.7). This is in agreement with the results of Ananth and co-workers, who found a relative risk of 2.45 for placental abruption among women with maternal anemia. Increased risk of pregnancy complications have been 16 reported among women with high Hb values, although no such relationship could be seen in this study.
A potential limitation of our study is that it is hospital-based. On the other hand, Womens clinic at Malmö University Hospital is the only delivery unit in the city, and the vast majority of women (i.e., > 95% of the population of Malmö) deliver at this unit. A second and the major drawback is the retrospective case-control design with all its limitations. Furthermore, in studies regarding placental abruption, there is a risk of bias due to both over-and underdiagnosis. However, the incidence of placental abruption in our population is in the same size as most other studies. One strength of this study is that most previously known risk factors for placental abruption were of similar size, as reported earlier. The routine dating of 4 pregnancy by ultrasound at 18 to 20 weeks of gestation, used here in the definition of IUGR and fetal loss, would represent another strength. In addition, ours is a fairly large study, including both personal interviews and an examination of medical records. Finally, the major strength is the use of a large prospectively collected unselected control group.
In conclusion, we found the history of second trimester, third trimester, and repeated fetal loss were significant risk factors for placental abruption. We constructed a risk score that may be used to access the risk of developing placental abruption. This may be used clinically to determine appropriate monitoring in cases of third trimester hemorrhage or premature contractions. Variables with roughly OR = 3 were assigned 1 point (second rimester fetal loss, repeated fetal loss, preeclampsia, IUGR, high maternal age, smoking, family history of thromboembolism, multiple pregnancy), prior stillbirth 2 points, and prior placental abruption 3 points. The points are added forming a risk score.
